KR20080104160A - 항-igf-1r 인간 단일클론 항체 제형 - Google Patents
항-igf-1r 인간 단일클론 항체 제형 Download PDFInfo
- Publication number
- KR20080104160A KR20080104160A KR1020087023673A KR20087023673A KR20080104160A KR 20080104160 A KR20080104160 A KR 20080104160A KR 1020087023673 A KR1020087023673 A KR 1020087023673A KR 20087023673 A KR20087023673 A KR 20087023673A KR 20080104160 A KR20080104160 A KR 20080104160A
- Authority
- KR
- South Korea
- Prior art keywords
- igf
- histidine
- polysorbate
- formulation
- mlhumab
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Mycology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06111848 | 2006-03-28 | ||
EP06111848.5 | 2006-03-28 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20080104160A true KR20080104160A (ko) | 2008-12-01 |
Family
ID=37025222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020087023673A KR20080104160A (ko) | 2006-03-28 | 2007-03-19 | 항-igf-1r 인간 단일클론 항체 제형 |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1998806A1 (fr) |
JP (1) | JP2009531371A (fr) |
KR (1) | KR20080104160A (fr) |
CN (1) | CN101410137A (fr) |
AR (1) | AR060130A1 (fr) |
AU (1) | AU2007229554A1 (fr) |
BR (1) | BRPI0709229A2 (fr) |
CA (1) | CA2647111A1 (fr) |
CL (1) | CL2007000797A1 (fr) |
CR (1) | CR10295A (fr) |
EC (1) | ECSP088778A (fr) |
IL (1) | IL193904A0 (fr) |
MA (1) | MA30345B1 (fr) |
MX (1) | MX2008012295A (fr) |
NO (1) | NO20083895L (fr) |
RU (1) | RU2008142359A (fr) |
TW (1) | TW200815029A (fr) |
WO (1) | WO2007110339A1 (fr) |
Families Citing this family (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2007331712A1 (en) * | 2006-12-11 | 2008-06-19 | F. Hoffmann-La Roche Ag | Abeta antibody parenteral formulation |
GB0702888D0 (en) * | 2007-02-14 | 2007-03-28 | Glaxo Group Ltd | Novel Antibodies |
CA2681743A1 (fr) * | 2007-03-22 | 2008-09-25 | Imclone Llc | Formulations d'anticorps stables |
CA2693611A1 (fr) * | 2007-07-10 | 2009-01-15 | F. Hoffmann-La Roche Ag | Nouvelle formulation |
JP5205470B2 (ja) * | 2007-11-29 | 2013-06-05 | エフ.ホフマン−ラ ロシュ アーゲー | 免疫グロブリン凝集物 |
UA101487C2 (en) * | 2007-12-21 | 2013-04-10 | Ф. Хоффманн-Ля Рош Аг | Humanized b-ly1 antibody formulation |
WO2010069858A1 (fr) * | 2008-12-19 | 2010-06-24 | F. Hoffmann-La Roche Ag | Composition pharmaceutique |
WO2010146059A2 (fr) | 2009-06-16 | 2010-12-23 | F. Hoffmann-La Roche Ag | Biomarqueurs pour une thérapie par inhibiteur d'igf-1r |
US9345661B2 (en) | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
SG182304A1 (en) * | 2009-12-29 | 2012-08-30 | Hoffmann La Roche | Antibody formulation |
KR20130086144A (ko) * | 2010-05-28 | 2013-07-31 | 노보 노르디스크 에이/에스 | 항체 및 보존제를 포함하는 안정한 다중-투여 조성물 |
LT2691112T (lt) | 2011-03-31 | 2018-07-25 | Merck Sharp & Dohme Corp. | Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai |
CN102363040B (zh) * | 2011-10-21 | 2013-05-01 | 北京锐瑟科技有限公司 | 用于粘膜组织的抗微生物肽制剂 |
CA2904806C (fr) | 2013-04-29 | 2021-11-23 | F. Hoffmann-La Roche Ag | Anticorps modifies se liant au fcrn humain et procedes d'utilisation |
CN103505729B (zh) * | 2013-05-24 | 2015-10-28 | 华北制药集团新药研究开发有限责任公司 | 一种稳定的狂犬病毒人源抗体组合制剂 |
CN104707146B (zh) * | 2013-12-16 | 2019-04-16 | 浙江海正药业股份有限公司 | 一种含有阿达木单抗的药物组合物 |
RU2698969C2 (ru) | 2014-01-15 | 2019-09-02 | Ф.Хоффманн-Ля Рош Аг | Варианты fc-области с улучшенной способностью связываться с белком а |
JP6707469B2 (ja) * | 2014-05-28 | 2020-06-10 | ノノ インコーポレイテッド | アセチル化スカベンジャーを含むTat−NR2B9cの凍結乾燥製剤 |
TW201628649A (zh) * | 2014-10-09 | 2016-08-16 | 再生元醫藥公司 | 減少醫藥調配物中微可見顆粒之方法 |
RU2020124105A (ru) | 2015-06-24 | 2020-09-18 | Ф. Хоффманн-Ля Рош Аг | Антитела против трансферринового рецептора, обладающие индивидуализированной аффинностью |
MX2018003306A (es) * | 2015-09-28 | 2018-05-16 | Suzhou Suncadia Biopharmaceuticals Co Ltd | Preparacion farmaceutica de anticuerpo anti-pd-1 estable y aplicacion del mismo en medicina. |
AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
CR20180149A (es) | 2015-10-02 | 2018-04-05 | Hoffmann La Roche | Anticuerpos biespecíficos contra el cd20 humano y el receptor de transferrina humano y métodos de uso |
CN106199007B (zh) * | 2016-08-03 | 2017-04-05 | 烟台普罗吉生物科技发展有限公司 | 蛋白保护剂 |
MX2019000935A (es) | 2016-08-16 | 2019-07-04 | Regeneron Pharma | Metodos para cuantificar anticuerpos individuales de una mezcla. |
CN109923411B (zh) | 2016-10-25 | 2022-05-31 | 里珍纳龙药品有限公司 | 用于色谱数据分析的方法和系统 |
JOP20190260A1 (ar) | 2017-05-02 | 2019-10-31 | Merck Sharp & Dohme | صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها |
RU2019138507A (ru) | 2017-05-02 | 2021-06-02 | Мерк Шарп И Доум Корп. | Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1 |
TW202005694A (zh) | 2018-07-02 | 2020-02-01 | 美商里珍納龍藥品有限公司 | 自混合物製備多肽之系統及方法 |
CN114324882B (zh) * | 2020-10-12 | 2022-12-27 | 广东菲鹏生物有限公司 | 蛋白稳定剂及其应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3919235B2 (ja) * | 1997-06-13 | 2007-05-23 | ジェネンテク,インコーポレイテッド | 抗体製剤 |
WO2002053596A2 (fr) * | 2001-01-05 | 2002-07-11 | Pfizer Inc. | Anticorps anti-recepteur du facteur de croissance insulinoide i |
DE60235013D1 (de) * | 2001-07-25 | 2010-02-25 | Facet Biotech Corp | Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab |
ES2383014T3 (es) * | 2003-04-02 | 2012-06-15 | F. Hoffmann-La Roche Ag | Anticuerpos contra el factor I de crecimiento similar a insulina y usos de los mismos |
ZA200507757B (en) * | 2003-04-04 | 2007-01-31 | Genentech Inc | High concentration antibody and protein formulations |
AR046071A1 (es) * | 2003-07-10 | 2005-11-23 | Hoffmann La Roche | Anticuerpos contra el receptor i del factor de crecimiento de tipo insulinico y los usos de los mismos |
UA85058C2 (ru) * | 2003-08-13 | 2008-12-25 | Пфайзер Продактс Инк. | Модифицированное моноклональное антитело человека, которое специфически связывается с рецептором подобного к инсулину фактора роста i человека (igf-ir) |
-
2007
- 2007-03-19 EP EP07727047A patent/EP1998806A1/fr not_active Withdrawn
- 2007-03-19 MX MX2008012295A patent/MX2008012295A/es active IP Right Grant
- 2007-03-19 KR KR1020087023673A patent/KR20080104160A/ko not_active Application Discontinuation
- 2007-03-19 RU RU2008142359/15A patent/RU2008142359A/ru not_active Application Discontinuation
- 2007-03-19 CA CA002647111A patent/CA2647111A1/fr not_active Abandoned
- 2007-03-19 WO PCT/EP2007/052569 patent/WO2007110339A1/fr active Application Filing
- 2007-03-19 JP JP2009502016A patent/JP2009531371A/ja active Pending
- 2007-03-19 BR BRPI0709229-6A patent/BRPI0709229A2/pt not_active IP Right Cessation
- 2007-03-19 CN CNA2007800114320A patent/CN101410137A/zh active Pending
- 2007-03-19 AU AU2007229554A patent/AU2007229554A1/en not_active Abandoned
- 2007-03-26 TW TW096110388A patent/TW200815029A/zh unknown
- 2007-03-26 CL CL2007000797A patent/CL2007000797A1/es unknown
- 2007-03-26 AR ARP070101241A patent/AR060130A1/es not_active Application Discontinuation
-
2008
- 2008-09-04 IL IL193904A patent/IL193904A0/en unknown
- 2008-09-11 NO NO20083895A patent/NO20083895L/no not_active Application Discontinuation
- 2008-09-17 CR CR10295A patent/CR10295A/es not_active Application Discontinuation
- 2008-09-26 EC EC2008008778A patent/ECSP088778A/es unknown
- 2008-10-20 MA MA31308A patent/MA30345B1/fr unknown
Also Published As
Publication number | Publication date |
---|---|
TW200815029A (en) | 2008-04-01 |
AU2007229554A1 (en) | 2007-10-04 |
EP1998806A1 (fr) | 2008-12-10 |
CR10295A (es) | 2008-10-06 |
IL193904A0 (en) | 2011-08-01 |
RU2008142359A (ru) | 2010-05-10 |
MX2008012295A (es) | 2008-10-09 |
ECSP088778A (es) | 2008-10-31 |
CL2007000797A1 (es) | 2008-01-25 |
CN101410137A (zh) | 2009-04-15 |
CA2647111A1 (fr) | 2007-10-04 |
JP2009531371A (ja) | 2009-09-03 |
NO20083895L (no) | 2008-10-24 |
BRPI0709229A2 (pt) | 2011-06-28 |
MA30345B1 (fr) | 2009-04-01 |
WO2007110339A1 (fr) | 2007-10-04 |
AR060130A1 (es) | 2008-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20080104160A (ko) | 항-igf-1r 인간 단일클론 항체 제형 | |
KR20180100439A (ko) | 이중특이적 항체 작제물을 포함하는 약제학적 조성물 | |
US20100260766A1 (en) | Stable antibody formulations | |
US20100158919A1 (en) | Pharmaceutical Composition | |
US20100158925A1 (en) | Lyophilized formulations of anti-egfr antibodies | |
JP7475335B2 (ja) | Csf-1r抗体製剤 | |
WO2007095337A2 (fr) | formulation d'anticorps | |
TW201420601A (zh) | 抗tslp抗體之安定調配物 | |
EP3991745A1 (fr) | Préparations contenant un anticorps bispécifique anti-cd47/pd-l1, procédé de préparation associé et leur utilisation | |
JP2022521624A (ja) | 抗cd47抗体を含む製剤、その調製方法および使用 | |
KR20230058432A (ko) | 약제학적 제형 | |
US20200129633A1 (en) | Pharmaceutical composition comprising c-met antibody-drug conjugate and use thereof | |
JP2023511356A (ja) | 組換え完全ヒト抗tigitモノクローナル抗体製剤及びその調製方法と使用 | |
CN114206382B (zh) | 包含抗pd-1/her2双特异性抗体的制剂及其制备方法和用途 | |
TW202342534A (zh) | 一種雙特異性抗原結合分子及其應用 | |
CN116474090A (zh) | 药物组合物 | |
CN114832102A (zh) | 一种稳定的抗egfr抗体组合物 | |
CN112675300A (zh) | 包含抗gitr抗体的制剂及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E601 | Decision to refuse application |